Table 2.
Safety of CMV-CTLs infusion
| Characteristics | Transplant donor CMV-CTLs (n = 62) | Third-party CMV-CTLs (n = 31) | P value |
|---|---|---|---|
| Number of infusions (n, %) | |||
| 1 | 51 (82.30) | 13 (41.90) | <0.01 |
| 2 | 7 (11.29) | 6 (19.35) | |
| ≥3 | 4 (6.45) | 12 (38.70) | |
| Immediate infusion-related toxicities (n, %) | 2 (3.22) | 2 (6.45) | 0.60 |
| Cytokine release syndrome (n, %) | 0 (0.00) | 0 (0.00) | 1 |
| Maximal acute GVHD after infusions (n, %) | 0.81 | ||
| I-II | 7 (11.29) | 3 (9.68) | |
| III-IV | 0 (0.00) | 0 (0.00) | |
| Death | |||
| Total causes | 12 (19.35) | 7 (22.58) | 0.79 |
| Treatment-ralated events | 11 (17.74) | 7 (22.58) | 0.59 |
Abbreviations: GVHD graft-versus-host disease; CMV-CTLs Cytomegalovirus-specific cytotoxic T lymphocytes